Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.
The post Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition appeared first on MedCity News.
